NCT01993212View on ClinicalTrials.gov

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Secondary Hypogonadism
Interventions
DRUG

Androxal 12.5 mg or 25 mg

DRUG

AndroGel 1.62%

DRUG

Placebo Capsules

DRUG

Placebo Gel

Trial Locations (8)

Unknown

Jacksonville

Albany

Raleigh

Cleveland

Medford

Warwick

Houston

Webster

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01993212 - A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% | Biotech Hunter | Biotech Hunter